Yuankai Shi, Phd
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
5
4
2
N/A
0
4
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+4 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (5)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Dong Wang, PhD
Daping Hospital & Research Institute of Surgery of the Third Military Medical University
Shared therapeutic areas:
Worked with same sponsors:
Zefei Jiang, PhD
Hospital Affiliated to Academy Military Medical Science
Shared therapeutic areas:
Worked with same sponsors:
Kai Li, PhD
Tianjin Medical University Cancer Institute and Hospital
Shared therapeutic areas:
Worked with same sponsors:
Yan Sun, PhD
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Shared therapeutic areas:
Worked with same sponsors:
Jun Ren, PhD
Peking University Cancer Hospital & Institute
Shared therapeutic areas:
Worked with same sponsors:
Xichun Hu, PhD
Fudan University
Shared therapeutic areas:
Worked with same sponsors:
Ingrid Mayer, MD
Vanderbilt-Ingram Cancer Center
Shared therapeutic areas:
Scott Holden, M.D.
Genentech, Inc.
Shared therapeutic areas:
Herui Yao, PhD
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Shared therapeutic areas:
Kari Wisinski, MD
University of Wisconsin, Madison
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (5)
Showing 5 of 5 trials
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma
Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects
Study of Cipterbin®, Used Alone or With Vinorelbine in Patients With HER2/Neu-overexpressed Metastatic Breast Cancer
All 5 trials loaded